IRIS Accounts Production v24.3.2.46 SC280028 director 1.7.23 30.6.24 30.6.24 false true false false false true false X Ordinary 1.00000 Y Ordinary 1.00000 Deferred shares 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC2800282023-06-30SC2800282024-06-30SC2800282023-07-012024-06-30SC2800282022-06-30SC2800282022-07-012023-06-30SC2800282023-06-30SC280028ns15:Scotland2023-07-012024-06-30SC280028ns14:PoundSterling2023-07-012024-06-30SC280028ns10:Director12023-07-012024-06-30SC280028ns10:PrivateLimitedCompanyLtd2023-07-012024-06-30SC280028ns10:SmallEntities2023-07-012024-06-30SC280028ns10:AuditExempt-NoAccountantsReport2023-07-012024-06-30SC280028ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-30SC280028ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-30SC280028ns10:FullAccounts2023-07-012024-06-30SC28002812023-07-012024-06-30SC280028ns10:OrdinaryShareClass12023-07-012024-06-30SC280028ns10:OrdinaryShareClass22023-07-012024-06-30SC280028ns10:OrdinaryShareClass32023-07-012024-06-30SC280028ns10:RegisteredOffice2023-07-012024-06-30SC280028ns5:CurrentFinancialInstruments2024-06-30SC280028ns5:CurrentFinancialInstruments2023-06-30SC280028ns5:ShareCapital2024-06-30SC280028ns5:ShareCapital2023-06-30SC280028ns5:RetainedEarningsAccumulatedLosses2024-06-30SC280028ns5:RetainedEarningsAccumulatedLosses2023-06-30SC280028ns5:NetGoodwill2023-07-012024-06-30SC280028ns5:IntangibleAssetsOtherThanGoodwill2023-07-012024-06-30SC280028ns5:LeaseholdImprovements2023-07-012024-06-30SC280028ns5:FurnitureFittings2023-07-012024-06-30SC280028ns5:ComputerEquipment2023-07-012024-06-30SC280028ns5:NetGoodwill2023-06-30SC280028ns5:NetGoodwill2024-06-30SC280028ns5:NetGoodwill2023-06-30SC280028ns5:LeaseholdImprovements2023-06-30SC280028ns5:FurnitureFittings2023-06-30SC280028ns5:ComputerEquipment2023-06-30SC280028ns5:LeaseholdImprovements2024-06-30SC280028ns5:FurnitureFittings2024-06-30SC280028ns5:ComputerEquipment2024-06-30SC280028ns5:LeaseholdImprovements2023-06-30SC280028ns5:FurnitureFittings2023-06-30SC280028ns5:ComputerEquipment2023-06-30SC280028ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-30SC280028ns5:WithinOneYearns5:CurrentFinancialInstruments2023-06-30SC280028ns5:DeferredTaxation2023-06-30SC280028ns5:DeferredTaxation2023-07-012024-06-30SC280028ns5:DeferredTaxation2024-06-30SC280028ns10:OrdinaryShareClass12024-06-30SC280028ns10:OrdinaryShareClass22024-06-30SC280028ns10:OrdinaryShareClass32024-06-30SC280028ns5:RetainedEarningsAccumulatedLosses2023-06-30SC280028ns5:RetainedEarningsAccumulatedLosses2023-07-012024-06-30
REGISTERED NUMBER: SC280028 (Scotland)















Unaudited Financial Statements for the Year Ended 30 June 2024

for

Dalhart Pharmacy Ltd.

Dalhart Pharmacy Ltd. (Registered number: SC280028)






Contents of the Financial Statements
for the Year Ended 30 June 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Dalhart Pharmacy Ltd.

Company Information
for the Year Ended 30 June 2024







DIRECTOR: Christian Barry





REGISTERED OFFICE: 35 Galloway Street
Dumfries
DG2 7TN





REGISTERED NUMBER: SC280028 (Scotland)





ACCOUNTANTS: Stevenson & Kyles
Chartered Accountants
25 Sandyford Place
Glasgow
G3 7NG

Dalhart Pharmacy Ltd. (Registered number: SC280028)

Balance Sheet
30 June 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - 38,763
Tangible assets 5 36,704 43,830
36,704 82,593

CURRENT ASSETS
Stock 106,898 104,242
Debtors 6 1,365,436 1,246,071
Cash at bank and in hand 147,941 186,483
1,620,275 1,536,796
CREDITORS
Amounts falling due within one year 7 497,918 627,264
NET CURRENT ASSETS 1,122,357 909,532
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,159,061

992,125

PROVISIONS FOR LIABILITIES 8 8,034 7,404
NET ASSETS 1,151,027 984,721

CAPITAL AND RESERVES
Called up share capital 9 433,333 433,333
Retained earnings 10 717,694 551,388
SHAREHOLDERS' FUNDS 1,151,027 984,721

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Dalhart Pharmacy Ltd. (Registered number: SC280028)

Balance Sheet - continued
30 June 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 26 March 2025 and were signed by:





Christian Barry - Director


Dalhart Pharmacy Ltd. (Registered number: SC280028)

Notes to the Financial Statements
for the Year Ended 30 June 2024

1. STATUTORY INFORMATION

Dalhart Pharmacy Ltd. is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is stated net of value added tax for over the counter sales and gross for NHS sales. Turnover from the sale of over the counter goods is recognised when the payment is recorded in the till and the NHS income is recognised when the client receives a PPD9 confirming the sale.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of various businesses, is being written off evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 15% on reducing balance
Fittings and equipment - 15% on reducing balance
Computer equipment - 33.33% on cost

Stocks
Stock are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Dalhart Pharmacy Ltd. (Registered number: SC280028)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

2. ACCOUNTING POLICIES - continued

Financial instruments
Trade debtors
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors
Trade creditors are amounts due to suppliers for goods or services obtained in the ordinary course of business. Trade creditors are recognised initially at the transaction price and subsequently measured at amortized cost using the effective interest method. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Dalhart Pharmacy Ltd. (Registered number: SC280028)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

2. ACCOUNTING POLICIES - continued

Grant income
Where applicable, grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and that the company will comply with all attached conditions. Where the grant income relates to a particular expense item, the grant income is recognised in the profit and loss account over the same period as the expense it is intended to compensate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 9 (2023 - 10 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 July 2023
and 30 June 2024 805,546
AMORTISATION
At 1 July 2023 766,783
Amortisation for year 38,763
At 30 June 2024 805,546
NET BOOK VALUE
At 30 June 2024 -
At 30 June 2023 38,763

Dalhart Pharmacy Ltd. (Registered number: SC280028)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

5. TANGIBLE FIXED ASSETS
Improvements Fittings
to and Computer
property equipment equipment Totals
£    £    £    £   
COST
At 1 July 2023 39,800 123,988 15,104 178,892
Additions - - 6,700 6,700
At 30 June 2024 39,800 123,988 21,804 185,592
DEPRECIATION
At 1 July 2023 39,800 80,158 15,104 135,062
Charge for year - 12,523 1,303 13,826
At 30 June 2024 39,800 92,681 16,407 148,888
NET BOOK VALUE
At 30 June 2024 - 31,307 5,397 36,704
At 30 June 2023 - 43,830 - 43,830

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 241,183 315,168
Other debtors 1,124,253 930,903
1,365,436 1,246,071

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 382,542 535,421
Taxation and social security 75,217 56,262
Other creditors 40,159 35,581
497,918 627,264

8. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax 8,034 7,404

Dalhart Pharmacy Ltd. (Registered number: SC280028)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

8. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Balance at 1 July 2023 7,404
Provided during year 630
Balance at 30 June 2024 8,034

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
100,000 X Ordinary £1 100,000 100,000
33,333 Y Ordinary £1 33,333 33,333
300,000 Deferred shares £1 300,000 300,000
433,333 433,333

10. RESERVES
Retained
earnings
£   

At 1 July 2023 551,388
Profit for the year 166,306
At 30 June 2024 717,694

11. ULTIMATE CONTROLLING PARTY

The company is under the control of the director, Christian Barry , by virtue of his shareholding in the parent company, Teleta Healthcare Limited.